Vanguard Global Advisers
PLYX

Vanguard Global Advisers’s Polaryx Therapeutics Inc PLYX Stock Holding History

Vanguard Global Advisers’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8K Hold
6,318
– – ﹤0.01% 3375
2026
Q1 		$47.8K Buy
+6,318
New +$40.8K ﹤0.01% 3046

Other funds holding PLYX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Global Advisers's PLYX Position: Q2 2026 in Review

Vanguard Global Advisers held its Polaryx Therapeutics Inc (PLYX) position steady in Q2 2026 at 6,318 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3375.

Vanguard Global Advisers first reported a position in PLYX in Q1 2026 and has held it in 2 quarters since. The position peaked at $47.8K in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

  • Vanguard Global Advisers held 6,318 shares of Polaryx Therapeutics Inc worth $16.8K as of Q2 2026.
  • Vanguard Global Advisers left its Polaryx Therapeutics Inc share count unchanged in Q2 2026.
  • Polaryx Therapeutics Inc made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3375 holding.
  • Vanguard Global Advisers first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Polaryx Therapeutics Inc position peaked at $47.8K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.